283 related articles for article (PubMed ID: 25350003)
1. TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.
Israely T; Melamed S; Achdout H; Erez N; Politi B; Waner T; Lustig S; Paran N
PLoS One; 2014; 9(10):e110545. PubMed ID: 25350003
[TBL] [Abstract][Full Text] [Related]
2. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
3. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
6. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
8. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
10. Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination.
Trojan A; Rajeswaran R; Montemurro M; Mütsch M; Steffen R
J Clin Virol; 2007 Sep; 40(1):80-3. PubMed ID: 17644471
[TBL] [Abstract][Full Text] [Related]
11. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
12. Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis.
Boivin N; Menasria R; Piret J; Boivin G
Antiviral Res; 2012 Dec; 96(3):414-21. PubMed ID: 23043942
[TBL] [Abstract][Full Text] [Related]
13. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.
Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS
Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115
[TBL] [Abstract][Full Text] [Related]
14. The generation of CD8+ T-cell population specific for vaccinia virus epitope involved in the antiviral protection against ectromelia virus challenge.
Gierynska M; Szulc-Dabrowska L; Dzieciatkowski T; Golke A; Schollenberger A
Pathog Dis; 2015 Dec; 73(9):ftv088. PubMed ID: 26474845
[TBL] [Abstract][Full Text] [Related]
15. Protection of mice against the highly pathogenic VV
Bissa M; Quaglino E; Zanotto C; Illiano E; Rolih V; Pacchioni S; Cavallo F; De Giuli Morghen C; Radaelli A
Antiviral Res; 2016 Oct; 134():182-191. PubMed ID: 27637905
[TBL] [Abstract][Full Text] [Related]
16. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
[TBL] [Abstract][Full Text] [Related]
17. The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.
Denzler KL; Schriewer J; Parker S; Werner C; Hartzler H; Hembrador E; Huynh T; Holechek S; Buller RM; Jacobs BL
Vaccine; 2011 Dec; 29(52):9691-6. PubMed ID: 21983358
[TBL] [Abstract][Full Text] [Related]
18. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.
Morikawa S; Sakiyama T; Hasegawa H; Saijo M; Maeda A; Kurane I; Maeno G; Kimura J; Hirama C; Yoshida T; Asahi-Ozaki Y; Sata T; Kurata T; Kojima A
J Virol; 2005 Sep; 79(18):11873-91. PubMed ID: 16140764
[TBL] [Abstract][Full Text] [Related]
19. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
